Review Article

Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer

Xiaowen Sun,1 Lu Gan,2 Aru Na,3 Lingling Ge,4 Baoqing Chen,5 and Jiaming Liu6

1Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
2Laboratory of Anesthesia and Critical Care Medicine, Translational Neuroscience Centre, West China Hospital, Sichuan University, Chengdu, China
3Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, Sichuan Province, China
4West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
5Department of Radiation Oncology, State Key of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
6Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Correspondence should be addressed to Jiaming Liu; jm3099@163.com

Xiaowen Sun and Lu Gan contributed equally to this work.

Received 20 May 2019; Revised 24 August 2019; Accepted 26 October 2019; Published 28 November 2019

Guest Editor: Shuang Zhou

Immunotherapy for renal cell cancer (RCC) has witnessed several developments for more than two decades. Checkpoint inhibitors, including anti-CTLA-4 and anti-PD-1/PD-L1 blockers, have changed the treatment landscape for patients with advanced RCC in the past 3 years. Despite these advances, more than 55% RCC patients become resistant to different immunotherapies without other treatment combination. Among various attempts at overcoming resistance to immunotherapy, stereotactic body radiotherapy (SBRT) has been found to potentiate the activity of immunotherapy agents through several potential mechanisms, including normalization of microvessels to alleviate tumor hypoxia, improvement in efficient delivery of drugs, abundant neoantigen exposure, and recruitment of antitumor immune cells to alter the immunosuppressive tumor microenvironment. Preclinical studies and clinical case reports have predicted that the combination of SBRT, an immunotherapy, may lead to remarkable results. This review aims to provide the biological basis for the feasibility of combining SBRT to overcome immunotherapy resistance and to review the currently available clinical evidence of this combination therapy in patients with advanced RCC.

1. Introduction

Renal cell cancer (RCC) is the third most common urological carcinoma, and over 90% cases of RCC in adults is clear cell in histology [1, 2]. The prognosis of RCC cases depends on the disease stage, tumor properties, the state of tumor metastasis, accurate diagnosis, proper treatment, and so on [2]. Advance and metastatic cases still carry a poor prognosis with a 5-year survival of about 9–12% [3]. Furthermore, nearly 30% of RCC cases with early-stage diagnosis will suffer from recurrence and progression after surgical procedures partly because of pre-existing micrometastatic loci before the surgery or some uncertain reasons [4].

Therapeutic options for advanced RCC patients should be based on histology (clear cell or not clear cell) and the most widely used prognostic factor model is from the Memorial Sloan Kettering Cancer Center (MSKCC) with stratification in three prognostic categories (favorable, intermediate, and poor risk) [5]. Prognostic factors for multivariable analysis included five variables—Karnofsky performance status (KPS) less than 80%, interval from diagnosis to treatment of less than 1 year, serum lactate...
dehydrogenase (LDH) greater than 1.5 times the upper limit of normal (ULN), corrected serum calcium greater than the ULN, and serum hemoglobin less than the lower limit of normal (LLN). Patients with none of these risk factors are considered low risk or with good prognosis, those with one or two factors present are considered intermediate risk, and patients with three or more of the factors are considered poor risk. First-generation systemic therapy, comprising cytokine-based procedures including interferon-alpha (IFN-α) and interleukin-2 (IL-2), is recommended for advanced RCC patients since there is documented evidence for its effectiveness against advanced RCC. Targeted therapies including tyrosine kinase (TKI) and mTOR inhibitors, and antibodies against vascular endothelial factor (VEGF) and platelet-derived growth factor (PDGF), have tremendously improved clinical outcomes compared with cytokine therapy alone.

Development and progression of advanced RCC have been slowed or even arrested through immune checkpoint inhibitor (ICI) combination therapy (ipilimumab plus nivolumab), which, in patients with intermediate or poor risk, showed a better overall survival (OS) than VEGF-targeted therapy recently [6]. However, the objective response rate (ORR) is 42% in ICI combination therapy suggesting that most RCC patients are resistant to ICI combination therapy [6]. The lack of predictive biomarkers of high quality has resulted in missed treatment opportunities for RCC patients who could not benefit from ICI therapy. Therefore, it is crucial that RCC patients overcome resistance to treatment and to expand applicable people who could benefit from ICI therapies.

Although RCC was considered to be resistant to radiotherapy, this concept is being challenged, particularly in the past decade, due to the continuous advances and innovation in radiotherapy technology. Increased doses of radiotherapy to tumor lesions has been observed following significant improvement in the accuracy of radiotherapy, which achieved better control of the damage in surrounding normal tissue. Stereotactic body radiotherapy (SBRT), which comprises high doses of radiation delivered in fractions (usually ≤5), has evolved to become an important treatment strategy for both primary lesions and metastatic diseases in different organs for RCC patients. Several key biological pathways triggered by SBRT prime the system immune to eliminate tumor cells. Therefore, SBRT and immunotherapy display synergistic effects, which are reviewed in this study to determine the biological basis and current preclinical and clinical evidence for combination treatment of SBRT and immunotherapy.

2. Current Immunotherapy in Clinical Trials for Patients with Advanced RCC

Currently, five immunotherapy agents, IL2, IFN-α, ipilimumab, nivolumab, and pembrolizumab, have been approved for treating advanced RCC, either alone or in combination with other drugs. Current immunotherapies for patients with advanced clear cell or non-clear cell RCC are described in Table 1.

IL-2 and IFN-α are reported to achieve durable complete or partial response in only a small population of patients [9, 17]. For the majority, the benefit from cytokine-based therapy is limited and the trials to improve the effectiveness have met with efficacy uncertainties. High-dose IL-2 showed substantial toxicity in patients [18]. Thus, selection of patients treated with high-dose IL-2 mainly depends on safety and the tumor histology (clear cell approved), medical comorbidities, patient’s performance status, risk scores, and the patient’s attitude to treatment risk.

IFN-α plus VEGF-targeted therapies such as bevacizumab may improve the prognosis of RCC to a certain degree [10, 11], but whether toxicity was greater in the combination therapy arm remains controversial. However, IFN-α alone was inferior compared to the sorafenib (VEGF TKI) [12] or temsirolimus (mTOR inhibitor) monotherapy [13].

Ipilimumab is a selective antibody blocking the interaction between cytotoxic T-lymphocyte antigen 4 (CTLA-4) and its ligands CD80/CD86. Nivolumab selectively blocks the interaction between programmed death-1 (PD-1) and its ligands. The FDA approved nivolumab for previously treated advanced RCC patients. A multicenter phase III trial (CheckMate 214) compared ipilimumab plus nivolumab (ICI combination) followed by nivolumab monotherapy (N = 425) versus sunitinib monotherapy (N = 422) in patients with advanced RCC [6]. Both groups showed intermediate or poor risk. In comparison with sunitinib, patients receiving ICI had higher ORR (42% vs. 27%, p < 0.001), and ICI group showed a significant improvement in complete response (CR) rate (9% vs. 1%, p < 0.001) in intermediate- or poor-risk patients. The 18-month OS rate in the ICI group was 75% (95% confidence interval (CI): 70–78%), while it was 60% in the sunitinib group [6].

There is controversy over ICI combination therapy in previously untreated favorable-risk patients. Also, the study population in CheckMate 214 included favorable-risk patients treated with ICI combination (N = 125) or sunitinib (N = 124) [6]. Exploratory analyses of 18-month OS rate found that the favorable-risk patients benefited more from sunitinib (88% vs. 93%). The ORR (29% and 52%; p < 0.001) and median progression-free survival (PFS) (14.3 months vs 25.1 months; HR: 2.18; p < 0.001) were lower in favorable-risk patients taking ICI combination than sunitinib in this trial. However, the CR rates were 11% and 6% for the ICI combination and sunitinib groups, respectively. Conversely, a phase I trial (CheckMate 016) supported the use of ICI combination in patients at any risk with confirmed advanced clear cell RCC, including those who received prior therapy [14]. The study included patients with poor (N = 6), intermediate (N = 47), or favorable (N = 47) risks. Patients with favorable risk comprised 44.7% of those taking ICI combination. The data for the favorable-risk patients alone were not published, but the 2-year OS for the entire cohort was 67.3%. The confirmed ORR for the cohort was similar in both arms (40.4%) [14]. Because of these conflicting results, the FDA approval for nivolumab plus ipilimumab only included patients with intermediate- or poor-risk RCC for first-line therapy.

In another randomized phase III clinical trial (CheckMate 025), patients (N = 821) with previously treated (excluding mTOR inhibitors) advanced clear cell RCC were assigned to receive nivolumab or everolimus (a mTOR
inhibitor). The median OS of the nivolumab group and everolimus group were 25.0 months and 19.6 months, respectively. The ORR was also 5 times greater with nivolumab (25% vs. 5%; p < 0.001) [15].

Recently, an open-label, randomized phase III clinical trial (KEYNOTE-426) compared the efficacy of pembrolizumab (Keytruda, a PD-1 blocker) plus axitinib (a multitargeted tyrosine kinase inhibitor for VEGFR, c-kit, and PDGFR, N = 432) with sunitinib (a multitargeted tyrosine kinase inhibitor for PDGFR, VEGFR, and c-kit, N = 429) in previously untreated advanced RCC patients [16]. As a result, 89.9% patients in the pembrolizumab-axitinib group and 78.3% patients in the sunitinib group survived at 12 months in 12.8 months median follow-up. Median PFS durations were 15.1 months and 11.1 months in the pembrolizumab-axitinib group and in the sunitinib group, respectively (HR 0.69; 95% CI, 0.57–0.84; p < 0.001); ORRs were 59.3% and 35.7% in the pembrolizumab-axitinib group (95% CI, 54.5–63.9%) and in the sunitinib group (95% CI, 31.1–40.4%). Regardless of PDL-1 expression, pembrolizumab combined with axitinib benefited patients in all risk groups (favorable, intermediate, and poor risk) [16]. Due to the conspicuous advantage of pembrolizumab plus axitinib over sunitinib on ORR and PFS, the FDA approved pembrolizumab plus axitinib as first-line therapy of all risk groups (favorable, intermediate, and poor risk) [16].

A retrospective analysis of 35 patients with metastatic, non-clear cell RCC who received at least one dose of nivolumab showed that 20% of patients had partial response and 29% of patients had stable disease in 8.5 months median follow-up and 3.5 months median PFS [19]. McKay et al. found that of 43 patients with metastatic, non-clear cell RCC, 8 (19%) patients had modest responses to PD-1/PD-L1 and 4 (13%) patients who received PD-1/PD-L1 monotherapy showed an objective response [20].

In general, the next generation of immunotherapies (ICI: ipilimumab, nivolumab, and pembrolizumab) raised hopes for patients with advanced RCC. From the results reported

### Table 1: Main clinical trials of immunotherapy for advanced RCC.

| Type of RCC | Drug | Phase | No. of pts | Line of therapy | ORR | mPFS (month) | mOS (month) | Reference |
|-------------|------|-------|------------|----------------|-----|-------------|-------------|-----------|
| Undifferentiated | High-dose IL2 | 2 | 71 | ND | ORR = 17%; CR = 5.6% | NA | 15.5 | Atkins et al. [7] |
| Undifferentiated | High-dose IL2 | 3 | 96 | ND | ORR = 23.3%; CR = 8.4% | 14 | 17.1 | McDermott et al. [8] |
| Undifferentiated | IL2 plus IFNα-2a | 3 | 140 | ND | ORR = 13.6%; CR = 3.5% | NA | 17 | Negri et al. [9] |
| Clear cell | bevacizumab plus IFNα-2a; Arm 1: | 3 | 325 | ND | Arm 1: ORR = 31%; CR = 1%; Arm 2: ORR = 13%; CR = 2% | 10.2 | 18.3 | Escudier et al. [10]; Rini et al. [11] |
| Clear cell | IFNα-2a | 2 | 189 | First line | ORR = 39%; CR = 2% | 5.6 | NA | Escudier et al. [12] |
| Both clear cell and non-clear cell enrolled | Temsirolimus; Arm 1: | 3 | 209 | First line | Arm 1: ORR = 8.6%; Arm 2: ORR = 4.8%; Arm 3: ORR = 8.1% | 10.9 | 7.3 | 8.4 | Hudes et al. [13] |
| Clear cell | Nivolumab (N) plus ipilimumab (I) | 1 | N3I1 = 47; N1I3 = 47 | First line | Both ORR = 40.4% in the N3I1 and N1I3 arms; CR = 10.6% in the N3I1 arm and none in the N1I3 arm. | N3I1 = 7.7; N1I3 = 9.4 | Not reached in the N3I1 arm and 32.6 months in the N1I3 arm | Hammers et al. [14] |
| Clear cell | Nivolumab plus ipilimumab; Arm 2: sunitinib | 3 | 550 | 546 | First line | Arm 1: ORR = 42%; CR = 9%; Arm 2: ORR = 27%; CR = 1%; Arm 3: ORR = 25%; CR = 1%; Arm 1: | 11.6 | 2.8.4 Not reached in arm 1 and 26 months in arm 2 | Motzer et al. [6] |
| Clear cell | Nivolumab; Arm 1: | 3 | 821 | Second line or third line | Arm 2: ORR = 5%; CR < 1%; Arm 1: | Arm 1: 4.6; Arm 2: 4.4 | Arm 1: 25; Arm 2: 19.6 | Motzer et al. [15] |
| Clear cell | Pembrolizumab plus axitinib; Arm 2: sunitinib | 3 | 432 | 429 | First line | Arm 1: ORR = 59.3%; CR = 5.8%; Arm 2: ORR = 35.7%; CR = 1.9%; Arm 1: | 15.1; Arm 2: 11.1 | Not reached in both arms | Rini et al. [16] |
| RCC: renal cell cancer; pts: patients; ND: not demanded; ORR: objective response rate; mPFS: median progression-free survival; mOS: median overall survival; IL2: interleukin-2; CR: complete response. |
so far, clear cell RCC and intermediate-risk/poor-risk populations could benefit more than others. ICI therapies showed the potential of improving the ORR and PFS with or without anti-VEGF therapy, which also resulted with lower severe toxicities than high-dose IL2. However, the OS benefit of pembrolizumab plus axitinib over sunitinib remains unknown. Considerable efforts are nevertheless needed to reduce the resistance rate to immunotherapy and improve its efficiency.

### 3. Potential Mechanisms of Adding SBRT to Overcome the Resistance to Immunotherapy

There are several underlying mechanisms explaining how SBRT enhances immunotherapy efficacy in the tumor microvasculature as depicted in Figure 1.

#### 3.1. Tumor Microvasculature Response to SBRT

Folkman hypothesized that the most common pathway for new microvessel development in malignant tumors is angiogenesis [21]. In physiological conditions, pro- and antiangiogenic factors maintain a dynamic balance for the normal development of blood vessels. However, in malignant tumors, this balance is perturbed by hypoxia. Excessive proangiogenic factors promote abnormal growth of microvessel, which become disorganized and form tortuous, dilated, hyperpermeable, and dysfunctional microvessels, resulting in intensifying hypoxia and poor transportation efficiency within the tumor microenvironment. These abnormal microvessels impede immune cell migration, function, and transportation of therapeutics. The response of microvessels to SBRT, their normalization structure, and endothelial cell (EC) apoptosis determine the radiosensitivity of certain malignant tumors, including RCC. EC apoptosis might be particularly crucial for RCC because of its extensive microvasculature.

In 2003, Garcia-Barros and colleagues discovered that high-dose SBRT (more than 8–11 Gy) facilitates apoptosis of EC in a dose-dependent manner and normalizes tumor microvasculature [22]. More than 8–11 Gy radiation induced EC apoptosis, and single dose of 15–20 Gy radiation resulted in rapid EC apoptosis. With a single dose of 15 Gy, EC apoptosis, involving acid sphingomyelinase (ASMase), is initiated in one hour, reaches its peak in four hours, and ceases in six hours. ASMase hydrolyses sphingomyelin, a proapoptotic messenger that coordinates transmembrane signaling of FAS-FASL-mediated and tumor necrosis factor-(TNF-) receptor-mediated apoptosis and DR5-TRAIL-mediated apoptosis through death-inducing signaling complexes within seconds after irradiation and without DNA damage. Clustering of receptor-bearing rafts facilitates the stimulation of receptor-mediated apoptosis. Exclusion of survival-regulating proteins and growth factors from these clustered rafts might cause EC apoptosis. A previous study showed that ASMase<sup>−/−</sup> mice had double the growth rate of MCA129 fibrosarcoma and half the rate of EC apoptosis than ASMase<sup>+/+</sup> mice [22], suggesting that EC apoptosis plays an important role in tumor cell death. Sathishkumar et al. observed that patients having a complete or partial response after SBRT (15 Gy/1f) had substantially augmented or higher levels of a secretory form of ASMase (S-ASMase) activity before radiotherapy was given (high basal activity), while little-to-no increase in low basal activity was observed in nonresponders [23]. Furthermore, 60% of patients with clear-cell renal cancer are highly vascularized owing to transcriptional silencing (hypermethylation) or mutation of von Hippel–Lindau (VHL). Degradation of hypoxia-inducible factor-1 (HIF-1) requires pVHL, and deficiency in pVHL results in HIF-1 accumulation and angiogenesis.

Given that renal cancer is assumed to be sensitive to SBRT [24], it was found that EC damage appears to be induced by both SBRT and conventional fractionated radiation (CFRT). These contrasting results may be due to the fact that EC apoptosis contributes significantly to tumor cell elimination in SBRT, and EC apoptosis was merely due to low-dose irradiation of CFRT which may not induce tumor cell death effectively, as death signaling in EC is repressed by activation of HIF-1 in tumor cells [25].

Apart from EC apoptosis, SBRT enhances involvement of pericytes in tumor microvessels, and the pericyte-covered microvessels were functional with an increase in perfusion, which could alleviate hypoxia and improve transportation efficacy [26]. Thus, there is a normalization of blood microvessels, offering a “window of opportunity” for immune-cell migration and transportation of therapeutics.

#### 3.2. The Systemic Antitumor Effect of SBRT

Basic biological and clinical research in tumor radiotherapy have revealed that local radiotherapy, especially SBRT, can induce systemic antitumor effect in tumor lesions beyond the radiated field, termed the abscopal effect, which has been reported in various malignancies including melanoma, lymphoma, neuroblastoma, and RCC and particularly in pulmonary metastases. A valid hypothesis explaining the mechanism behind abscopal effect is that high-dose radiation can cause tumor cells to die within a short period and expose new tumor antigens, so that radiated tumor cells function as natural tumor vaccines after radiation exposure [27–29]. Concurrently, during the process of tumor cell death, damage-associated molecular patterns, such as HMGB1, ATP, and heat shock proteins, are also released in large quantities. These molecules can effectively induce dendritic cells (DCs) to recognize tumor-specific antigens resulting in their capture and migration of DCs to draining lymph nodes, where tumor antigens are presented to T cells [30], which in turn get activated and undergo massive proliferation. Activated effector T cells enter the circulatory system, recognize tumor cells far from the radiated field, and exert antitumor effects [31, 32].

To explore whether SBRT can enhance the expression of tumor-associated antigens in patients with advanced RCC, Singh et al. studied the response to SBRT in patients with advanced RCC. This study evaluated patients receiving neoadjuvant SBRT following surgery and found SBRT patients had higher expression of tumor-associated antigens (MUC-1, CA-9, 5T4, and NY-ESO-1) and costimulatory molecules ICAM-1 and CD80 compared with patients.
Moreover, the apoptosis inducers TNF-α (24–72 h after SBRT), IL-1α, IL-1β, IL-6, FASL, and TGF-β were released during radiotherapy; higher levels of TNF-α agreed with the abscopal effect and complete tumor response [23, 34].

4. Efficacy of SBRT in Patients with Advanced RCC

Results from several studies support that SBRT differs from CFRT for RCC patients, and SBRT is effective at controlling both primary and metastatic lesions of RCC, as summarized in Table 2.

4.1. SBRT Differs from CFRT in Treating Patients with RCC

In recent years, SBRT has been delivered to patients with advanced RCC, with results showing a slow but persistent shrinkage of the renal tumor after SBRT [50]. Compared with CFRT, in RCC with bone metastases, the median time to symptom relief between SBRT and CFRT was similar, but the symptom control rates of SBRT were much higher than those of CFRT [35]. Furthermore, the authors of the study also showed that the biologically effective dose (BED) ≥80 Gy was significant for better clinical response and was predictive of local control [35]. Similar results were reported by Altoos et al. showing SBRT-mediated control of thoracic, abdominal, and soft tissue lesions in RCC, with predictive factors for better local control being BED ≥100 Gy and dose per fraction ≥9 Gy [36]. An analysis of radiographic and symptomatic RT responses in 27 consecutive RCC patients with 37 lung lesions found that rates of radiographic local control with SBRT were much higher than CFRT [37]. To explore the difference between SBRT and CFRT on spine metastases from RCC, a total of 110 patients (34 CFRT; 76 SBRT) were retrospectively analyzed [51]. The researchers found that both CFRT (20 Gy/5f) and SBRT (15 Gy/1f) provided effective relief of symptomatic spine metastases from RCC, whereas CFRT relieved pain faster, and pain relief with SBRT was more durable [51].

4.2. SBRT Is Effective in Controlling Primary Renal Lesions

Results from several studies indicate that SBRT is effective in controlling primary renal lesions. For example, renal tumors treated with SBRT show significant reductions in growth rate and tumor size after radiation [52]. Furthermore, a prospective phase I trial suggested that SBRT might be an alternative to cytoreductive nephrectomy for inoperable patients with advanced RCC [39]. The median tumor size was increased 17.3% at 5.3 months, and the median OS was increased at 6.7 months [39]. Inadequate single doses (≤7 Gy) in this prospective study could be the reason for these moderate results. For asynchronous bilateral RCC...
Table 2: SBRT is effective in primary lesions and metastases of advance RCC.

| Study type          | No. of patients/lesions | SBRT target                  | SBRT regimen                          | Local control                                      | OS                  | AE (≥ Grade 3)                  | Ref                  |
|---------------------|-------------------------|-------------------------------|----------------------------------------|---------------------------------------------------|---------------------|---------------------------------|----------------------|
| Retrospective study | 50 lesions              | Bone metastasis              | Most common is 27 Gy/3f                | Rates at 12 and 24 months were both 74.9%          | NA                  | Grade 3 AE: 1 patient, dermatitis | Amini et al. [35]    |
|                     |                         |                               |                                        | Rates at 12, 24, and 36 months were 100%, 93.41%, and 93.41%, respectively |                     |                                 |                      |
|                     |                         |                               |                                        | Median OS about 32 months                         | NA                  |                                 |                      |
| Retrospective study | 36 lesions              | Thoracic, abdominal, and soft-tissue lesions | Most common is 50 Gy/5f               | Median SBRT dose and fraction were 50 Gy (range 25–60) and 3 (range 1–6) |                         |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        | 92.3% for median follow-up 16 months              | NA                  |                                 |                      |
| Retrospective study | 27 pts/37 lesions       | Lung metastasis              | Median SBRT dose and fraction were 50 Gy (range 25–60) and 3 (range 1–6) | Rates at 1, 3, and 5 years were 64.8, 43.2, and 43.2%, respectively |                     |                                 |                      |
|                     |                         |                               |                                        | Rates at 1, 3, and 5 years were 66.7, 53.3, and 35.6%, respectively |                     |                                 |                      |
|                     |                         |                               |                                        | Median 26 months                                   | 8.3 months          |                                 |                      |
|                     |                         |                               |                                        | (1.5–38)                                           |                     |                                 |                      |
| Retrospective study | 57 pts/88 lesions       | Spinal metastases            | Single fraction, median 15 Gy         | 92.3% for median follow-up 13.67 months           | NA                  |                                 |                      |
|                     |                         |                               |                                        | Estimated 3-year OS post-treatment was 72%, 95% CI (0.44–0.87) |                     |                                 |                      |
|                     |                         |                               |                                        |                                                   |                     |                                 |                      |
| Prospective phase I trial | 12 pts             | Primary renal lesions        | 25 Gy, 30 Gy, or 35 Gy in 5 fractions | Rates at 2 years was 100%                          | Rates at 2 years was 92% |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 9 pts                  | Bilateral primary renal lesions | 60–85 Gy was delivered at 5–7 Gy/fraction | Rates at 2 years was 92%                          | Rates at 2 years was 92% |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Prospective phase I trial | 15 pts             | Primary renal lesions        | 24–48 Gy/4f                           | 100% for median follow-up 13.67 months           | Rates at 2 years was 92% |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Prospective study | 37 pts                 | Primary renal lesions        | 26 Gy/1f for tumors ≤5 cm and 42 Gy/3f for tumors ≥5 cm | Rates at 2 years was 100%                          | Rates at 2 years was 92% |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 21 pts                 | Primary renal lesions        | 48 Gy/3f                              | Rates at 1 and 2 years were 92 and 84%, respectively | Rates at 1 and 2 years were 92% |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 32 pts/52 lesions       | Brain metastasis             | 22.0 Gy (range, 12.8–24.0 Gy)          | NA                                                | 6.3 months          |                                 |                      |
|                     |                         |                               |                                        |                                                    | (0.4–100.4 months) |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 16 pts/99 lesions       | Brain metastasis (≥5)        | SRS                                   | 91% of targets                                    | NA                  |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 81 pts/117 lesions      | Brain metastasis (from melanoma or renal cancer) | 18 Gy (range 15–20 Gy) | Rate at 1 year was 79.4% for renal cancer | NA                  |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 15 pts                 | Brain metastasis             | SRS                                   | NA                                                | 8.4 months          |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
| Retrospective study | 18 pts/39 lesions       | Oligometastatic renal cancer (extracranial) | 8–14 Gy × 3 fractions or 4–5 Gy × 10 fractions | Rate at 2 years was 91.4%                          | 2 years was 85% |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
|                     |                         |                               |                                        |                                                    |                     |                                 |                      |
SBRT Controls Intracranial and Extracranial Metastases in RCC. At present, several early studies have demonstrated that SBRT has an inhibitory effect on RCC metastases, including intracranial and extracranial metastases.

4.3.1. Intracranial Metastases Controlled by Stereotactic Radiosurgery (SRS). Brain metastasis (BM) usually indicates poor prognosis in patients with RCC. Whole brain radiation therapy (WBRT) is considered a standard treatment in patients with multiple (>5) BMs. However, WBRT (usually 2–3 Gy per fraction) has limited efficacy in patients with BM from radio-resistant tumors such as RCC and melanoma whose median survival is 2–4 months. Stereotactic radiosurgery (SRS) for BM from RCC has been regarded as an alternative to surgery and delivers high-dose radiation in no more than 3 fractions (usually only one fraction), but avoids the toxic effects of WBRT. Studies in this regard have shown local control in 24 of 32 renal patients with 52 metastases while 4 patients had local progression using SRS for brain metastases in patients, in which the median dose was 22.0 Gy (range, 12.8–24.0 Gy), and the median OS was 6.3 months (range, 0.4–100.4 months) [44]. To evaluate outcomes of SRS in 16 RCC patients with multiple (≥5) simultaneous BMs (99 lesions in total) treated with SRS showed OS after 6 months and 1 year to be 50% and 31%, respectively. The median OS was 7.1 months (range 1–21), and 91% patients were free from local failure [45]. Besides, it has been found that SRS dose >18 Gy was associated with improved survival in patients with RCC [53]. Using this dose (range 15–20 Gy), a study involving 81 patients treated with SRS for BM from melanoma or RCC showed actuarial OS rates at 6 months and 1 year of 55.4% and 30.2%, respectively, and one-year local control (LC) rate of 79.4% for RCC [46]. Another similar, but smaller, study involved BM from melanoma (N = 26) or RCC (N = 15) patients, which found the lack of statistical significant differences in OS between patients with RCC and melanoma (8.4 mo vs 5.0 mo, p = 0.11) [54].

The results of these studies indicated that the OS of patients with BM from RCC treated with SRS is about 6.3–8.4 months, which is much longer than patients who underwent WBRT. The lack of high-grade evidence in current retrospective studies warrants the need for prospective studies in order to guide clinical practice, with the inclusion of more numbers of BMs to make valid conclusions.

4.3.2. Extracranial Metastases Controlled by Stereotactic Radiosurgery (SRS). The ability of SBRT to control extracranial metastases in RCC was demonstrated in recent studies on 84 patients with 175 metastatic extracranial lesions who received SBRT (40–60 Gy/5f or 30–54 Gy/3f or 20–40 Gy/1f); the 1-year local control (LC) rate after SBRT was 91.2%, and one factor of local failure was BED >18 Gy was associated with improved survival in patients with RCC [53]. Using this dose (range 15–20 Gy), a study involving 81 patients treated with SRS for BM from melanoma or RCC showed actuarial OS rates at 6 months and 1 year of 55.4% and 30.2%, respectively, and one-year local control (LC) rate of 79.4% for RCC [46]. Another retrospective study of 48 patients treated for 70 spine metastases showed that the spine recurrence rates of 60% were mainly associated with salvage SBRT, which was only 20% for upfront SBRT. The study suggested that an early SBRT with higher doses could be more effective than salvage SBRT [49]. As mentioned above, SBRT effectively relieves symptomatic spine metastases in RCC. Compared with CFRT, SBRT trends to produce more durable pain relief [51], as demonstrated in 57 RCC patients (88 treatment) with spine metastasis, wherein Balagamwala et al. found that a single fraction SBRT achieved a median survival of 8.3 months and relieved pain rapidly with a median duration of 5.4 months of pain relief [38].

The currently available evidence reviewed in this study suggests that SBRT alone is effective for RCC, including primary lesions treatment and intracranial and extracranial metastases control; especially, patients with multiple intracranial metastases face poor prognosis. Single dose <7 Gy
might be ineffective to achieve satisfactory treatment results in RCC patients, but higher dose radiation in SBRT monotherapy exerted robust disease control with acceptable clinical risk.

5. Preclinical and Clinical Evidence for the Inclusion of SBRT to Overcome Resistance to Immunotherapy

5.1. Preclinical Evidence. The introduction of ICIs, initially with anti-CTLA-4 antibodies, initiated a revolution in oncology. The inclusion of radiotherapy to ICI, animal models, or clinical studies focusing on the integrating radiation and related drugs followed in an attempt to find effect of radiotherapy on immune activation in several solid tumors [55]. Under this strategy, combining radiation with immune-checkpoint blockade increased locoregional control of tumors [31, 56]. Furthermore, combination of local radiation with anti-CTLA-4 and anti-PD-1/PD-L1 inhibitors increased systemic disease control mediated by the abscopal effect [57]. An increase in complete regression of the irradiated primary tumor and reduced size of nonirradiated tumors outside the radiation field were observed when SBRT was combined with PD-1 blockade in melanoma and RCC models [58]. This effect was not attributed to tumor histology or host genetic background, but as it was tumor-specific, the effect was potentiated by PD-1 blockade, an abscopal tumor-specific immune response induced by radiotherapy in nonirradiated tumors [58]. The abscopal effect was exerted only in a small proportion of patients who received anti-CTLA-4 combined with radiotherapy, leading to PD-1/PDL1-mediated resistance to ipilimumab [57]. Another study showed blockade of adaptive immune resistance mediated by anti-PD-1/PDL1 antibodies upon localized radiation with anti-CTLA-4 therapy. Furthermore, nonredundant immune mechanisms mediated the superior activity of radiation and dual immune checkpoint blockade [59].

5.2. Clinical Evidence. Clinical evidence reporting combination of SBRT with immunotherapy in advanced RCC is scant. A phase-2 trial combining high-dose IL2 and SBRT in patients with metastatic RCC [60] showed that 1–3 lesion sites were treated with SBRT with a dose of 21–27 Gy for single fraction or 25–33 Gy for 3 fractions. The primary endpoint of the study—response rate—was 40%, with 1 patient presenting CR and 3 patients showing PR. The median duration of overall response (including CR and PR) was 5 months, and median stable disease (SD) duration was 6 months. Addition of SBRT to IL-2 increased the response rate in metastatic RCC patients by about 2-folds compared with IL-2 alone. Two cases have reported the induction of abscopal effect when SBRT was combined with ICI therapy in advanced RCC patients. One case reported by Xie et al. showed a systemic complete response to SBRT (32 Gy/4f) and pembrolizumab (anti-PD-1 antibody) in a patient with metastatic RCC [61]. The metastatic lymph nodes in the left mediastinum were irradiated with a total of 32 Gy administered in four fractions on four consecutive days [61]. The second case was that of a 24-year-old male with advanced clear-cell RCC and bone, lung, and nodal metastases who received SBRT (27 Gy/3f) to the sacrum metastatic mass and subsequent ipilimumab and nivolumab therapy [62]. The sacrum mass was obviously shrunk with the therapy and no radiological evidence for lung and nodal metastases was found more than 12 months after SBRT [62].

To determine the effect of combining SBRT with immunotherapy, we searched ClinicalTrials.gov for studies and identified 13 ongoing clinical trials (Table 3). The vast majority of these trials were phase-2 studies and combined ICIs and (or) high-dose IL2.

6. Discussion

Recently, a single-arm phase-2 trial, which combined SBRT and a PD-1 blocker (pembrolizumab), suggested PFS improvement without serious safety signals in patients with oligometastatic NSCLC [63]. Immunotherapy (especially ICI) offers hope for patients with advanced RCC, particularly when SBRT is offered in combination. High dose of radiation effectively results in abundant ECs apoptosis which aids in reducing and renormalizing microvessels in the tumor for better transportation of therapeutics and migration of immune cells. Furthermore, SBRT has the potential to prime the immune system by exposing a mass of tumor antigens after irradiation. We acknowledge that there is limited evidence regarding this hypothesis and additional clinical studies are needed. However, in our humble opinion, SBRT offers a promising strategy for overcoming the resistance to immunotherapy in advanced RCC. Nevertheless, limitation of the combined therapy exists as follows:

First, there exists the possibility of severe treatment-related adverse events. High-dose IL2 itself has shown to induce substantial toxicity. Furthermore, ICI therapy-induced acute kidney injuries such as acute tubulointerstitial nephritis, acute interstitial nephritis, and increased blood creatinine or acute renal failure have been reported [64–66]. As mentioned previously, application of SBRT to renal primary lesions could lead to dose-dependent renal dysfunction. Therefore, the combination of SBRT with PD-1/PD-L1 inhibitors will probably increase therapy-associated severe adverse events. Moreover, the incidence of other common treatment-related adverse events such as hypothyroidism and hyperthyroidism, which were the most frequent endocrine immune-related adverse events for PD-1/PD-L1 inhibitor alone, must be considered [67].

Second, the dose, fractions, and targets of SBRT plan are crucial, whereas a single dose <8 Gy might be insufficient and a higher dose presents a higher risk, particularly when combined with immunotherapy. Therefore, a dose-escalation study is warranted to maximize clinical efficacy with acceptable toxicities for prospective clinical trials. Encouraging results from preclinical and clinical studies support the synergistic effect of SBRT and ICI therapy against brain metastases from melanoma [68, 69]. Marrow-derived suppressor cells (MDSC) and immunosuppressive B cells could impede the antitumor activity induced by SBRT and immune
therapy [70, 71]. These immunosuppressive cells and heterogeneity in tumor might be the reasons for low incidence of abscopal effect in the clinic. Brooks and Chang suggested that we should abandon single-site radiation and that radiotherapy could be delivered to all targetable diseases to broaden the T-cell repertoire and maximize the activation of the immune response [72].

Third, an appropriate sequence of SBRT and immunotherapy should be planned with detailed consideration. Harris et al. reported that the highest antitumor immune response in the mouse model of prostate cancer was obtained by adding immunotherapy after 3–5 weeks of radiotherapy; however, there was no obvious antitumor immune response after the end of radiotherapy [73]. It has also been suggested that CTLA-4 antibodies should be used to deplete regulatory T cells prior to radiotherapy to obtain maximum immune effects [74].

Fourth, pembrolizumab plus axitinib have yielded outstanding results, suggesting the benefit of concurrent or sequential treatment with anti-VEGF therapy combined with SBRT and immunotherapy, especially for patients with multiple lesions, some of which may be unsuitable for SBRT. However, the potential toxicities of anti-VEGF therapy with SBRT and immunotherapy need more attention [75].

In conclusion, combination of SBRT with immunotherapy may unlock antitumor immune responses that have the potential of overcoming resistance to immunotherapy in patients with advanced RCC.

Conflicts of Interest

All the authors declare that there are no relevant conflicts of interest to disclose.

Authors’ Contributions

Xiaowen SUN collected, reviewed the main literature, and wrote the manuscript. Lu GAN supplemented the literature and revised the manuscript. Jiaming LIU pointed out writing design and revised the manuscript. Runa A, Lingling GE, and Baoqing Chen put up with helpful comments on the manuscript. All authors read and approved the final manuscript.
Acknowledgments

The study was supported by the National Natural Science Fund of China (31801066), National Natural Science Fund of China (31741034), Science and Technology Administration, Sichuan Province (2017ZSF0048), Health Committee, Sichuan Province (16PJ298), and 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZY2016104).

References

[1] L. Lipworth, R. E. Tarone, and J. K. McLaughlin, “The epidemiology of renal cell carcinoma,” Journal of Urology, vol. 176, no. 6, pp. 2353–2358, 2006.

[2] J. Bedke, T. Gauler, V. Grünwald et al., “Systemic therapy in metastatic renal cell carcinoma,” World Journal of Urology, vol. 35, no. 2, pp. 179–188, 2017.

[3] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA: A Cancer Journal for Clinicians, vol. 69, no. 1, pp. 7–34, 2019.

[4] A. C. Reese, J. M. Whitson, and M. V. Meng, “Natural history of untreated renal cell carcinoma with venous tumor thrombus,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 7, pp. 1305–1309, 2013.

[5] R. J. Motzer, J. Bacik, B. A. Murphy, P. Russo, and M. Mazumdar, “Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma,” Journal of Clinical Oncology, vol. 20, no. 1, pp. 289–296, 2002.

[6] R. J. Motzer, N. M. Tannir, D. F. McDermott et al., “Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma,” New England Journal of Medicine, vol. 378, no. 14, pp. 1277–1290, 2018.

[7] M. B. Atkins, J. Sparano, R. I. Fisher et al., “Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon-alfa-2b in advanced renal cell carcinoma,” Journal of Clinical Oncology, vol. 11, no. 4, pp. 661–670, 1993.

[8] D. F. McDermott, M. M. Regan, J. I. Clark et al., “Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 133–141, 2005.

[9] S. Negrier, B. Escudier, C. Lasset et al., “Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma,” New England Journal of Medicine, vol. 338, no. 18, pp. 1272–1278, 1998.

[10] B. Escudier, A. Pluzanska, P. Koralewski et al., “Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial,” The Lancet, vol. 370, no. 9605, pp. 2103–2111, 2007.

[11] B. I. Rini, S. Halabi, J. E. Rosenberg et al., “Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206,” Journal of Clinical Oncology, vol. 28, no. 13, pp. 2137–2143, 2010.

[12] B. Escudier, C. Szczylik, T. E. Hutson et al., “Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1280–1289, 2009.

[13] G. Hudes, M. Carducci, P. Tomczak et al., “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma,” New England Journal of Medicine, vol. 356, no. 22, pp. 2271–2281, 2007.

[14] H. J. Hammers, E. R. Plimack, J. R. Infante et al., “Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study,” Journal of Clinical Oncology, vol. 35, no. 34, pp. 3851–3858, 2017.

[15] R. J. Motzer, B. Escudier, D. F. McDermott et al., “Nivolumab versus everolimus in advanced renal-cell carcinoma,” New England Journal of Medicine, vol. 373, no. 19, pp. 1803–1813, 2015.

[16] B. I. Rini, E. R. Plimack, V. Stus et al., “Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma,” New England Journal of Medicine, vol. 380, no. 12, pp. 1116–1127, 2019.

[17] N. Javadpour and M. Lalehzarian, “A phase I-II study of high-dose recombinant human interleukin-2 in disseminated renal-cell carcinoma,” Seminars in Surgical Oncology, vol. 4, no. 3, pp. 207–209, 1988.

[18] J. A. Osman, P. C. Kohler, J. A. Hank et al., “Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin,” JNCI Journal of the National Cancer Institute, vol. 80, no. 18, pp. 1451–1461, 1988.

[19] V. S. Koshkin, P. C. Barata, T. Zhang et al., “Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma,” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, p. 9, 2018.

[20] R. R. McKay, D. Bossé, W. Xie et al., “The clinical activity of PD-1/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma,” Cancer Immunology Research, vol. 6, no. 7, pp. 758–765, 2018.

[21] L. M. Sherwood, E. E. Parris, and J. Folkman, “Tumor angiogenesis: therapeutic implications,” New England Journal of Medicine, vol. 285, no. 21, pp. 1182–1186, 1971.

[22] M. Garcia-Barros, “Tumor response to radiotherapy regulated by endothelial cell apoptosis,” Science, vol. 300, no. 5622, pp. 1155–1159, 2003.

[23] S. Sathishkumar, B. Boyanovsky, A. Karakashian et al., “Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis,” Cancer Biology & Therapy, vol. 4, no. 9, pp. 979–986, 2005.

[24] E. Jonasch, P. A. Futreal, I. J. Davis et al., “State of the science: an update on renal cell carcinoma,” Molecular Cancer Research, vol. 10, no. 7, pp. 859–880, 2012.

[25] Z. Fuks and R. Kolesnik, “Engaging the vascular component of the tumor response,” Cancer Cell, vol. 8, no. 2, pp. 89–91, 2005.

[26] J. Lan, X.-L. Wan, L. Deng et al., “Ablative hypofractionated radiotherapy normalizes tumor vasculature in Lewis lung carcinoma mice model,” Radiation Research, vol. 179, no. 4, pp. 458–464, 2013.

[27] M. M. Ahmed, J. W. Hodge, C. Guha, E. J. Bernhard, B. Vikram, and C. N. Coleman, “Harnessing the potential of radiation-induced immune modulation for cancer therapy,” Cancer Immunology Research, vol. 1, no. 5, pp. 280–284, 2013.

[28] S. C. Formenti and S. Demaria, “Radiation therapy to convert the tumor into an in situ vaccine,” International Journal of Radiation Oncology*Biology*Physics, vol. 84, no. 4, pp. 879–880, 2012.
[29] S. Demaria, E. B. Golden, and S. C. Formenti, “Role of local radiation therapy in cancer immunotherapy,” JAMA Oncology, vol. 1, no. 9, pp. 1325–1332, 2015.

[30] S. C. Formenti and S. Demaria, “Systemic effects of local radiotherapy,” The Lancet Oncology, vol. 10, no. 7, pp. 718–726, 2009.

[31] A. B. Sharabi, C. J. Nirschl, C. M. Kochel et al., “Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen,” Cancer Immunology Research, vol. 3, no. 4, pp. 345–355, 2015.

[32] A. B. Sharabi, M. Lim, T. L. DeWeese, and C. G. Drake, “Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy,” The Lancet Oncology, vol. 16, no. 13, pp. e498–e509, 2015.

[33] A. K. Singh, T. B. Winslow, M. H. Kermany et al., “A pilot study of stereotactic body radiation therapy combined with cytoreductive nephrectomy for metastatic renal cell carcinoma,” Clinical Cancer Research, vol. 23, no. 17, pp. 5055–5065, 2017.

[34] J. M. Kaminski, E. Shinohara, K. J. Niermann, A. Morimoto, and J. Brousal, “The controversial abscopal effect,” Cancer Treatment Reviews, vol. 31, no. 3, pp. 159–172, 2005.

[35] A. Amini, B. Altoos, M. T. Bourlon et al., “Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant?,” Practical Radiation Oncology, vol. 5, no. 6, pp. e589–e596, 2015.

[36] B. Altoos, A. Amini, M. Yacoub et al., “Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT),” Radiation Oncology, vol. 10, no. 1, 2015.

[37] B. M. Altoos, A. Amini, and M. T. Bourlon, “Is RCC truly radiosensitive? Local control rates of metastatic renal cell carcinoma (RCC) to the lung using stereotactic radiotherapy (SBRT),” Journal of Clinical Oncology, vol. 33, no. 7, p. 445, 2015.

[38] E. H. Balagamwala, L. Angelov, S. A. Koyfman et al., “Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma,” Journal of Neurosurgery: Spine, vol. 17, no. 6, pp. 556–564, 2012.

[39] R. J. M. Correa, B. Ahmad, A. Warner et al., “A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma,” Radiation Oncology, vol. 13, no. 1, 2018.

[40] Y.-J. Wang, T.-T. Han, J.-X. Xue et al., “Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma,” La Radiologia Medica, vol. 119, no. 11, pp. 878–883, 2014.

[41] L. Ponsky, S. S. Lo, Y. Zhang et al., “Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma,” Radiotherapy and Oncology, vol. 117, no. 1, pp. 183–187, 2015.

[42] S. Siva, D. Pham, T. Kron et al., “Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial,” BJU International, vol. 120, no. 5, pp. 623–630, 2017.

[43] I. D. Kaplan, A. Wagner, A. Mahadevan, and R. N. Dagooglu, “Stereotactic body radiosurgery for primary small renal tumors: a retrospective analysis,” Journal of Clinical Oncology, vol. 32, no. 4, p. 475, 2014.

[44] K. Shah, M. Surucu, E. Melian et al., “Intracranial control of renal cell carcinoma brain metastasis using Linac based stereotactic radiosurgery,” Neuro-Oncology, vol. 14, no. 6, 2012.

[45] A. M. Mohammadi, S. T. Chao, B. I. Rini, J. A. Garcia, J. H. Suh, and L. Angelov, “The role of stereotactic radiosurgery in the treatment of renal cell carcinoma patients with five or more brain metastases,” Journal of Clinical Oncology, vol. 30, no. 5, p. 410, 2012.

[46] C. Feng, J. Lemons, D. R. Raleigh et al., “Reconsidering radioresistance: Linac-based stereotactic radiosurgery for intracranial metastases from melanoma and renal cell carcinoma,” Neuro-Oncology, vol. 18, no. 6, p. 181, 2016.

[47] M. C. Ranck, D. W. Golden, K. S. Corbin et al., “Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma,” American Journal of Clinical Oncology, vol. 36, no. 6, pp. 589–595, 2013.

[48] C. J. Wang, A. Christie, M.-H. Lin et al., “Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases,” International Journal of Radiation Oncology* Biology* Physics, vol. 98, no. 1, pp. 91–100, 2017.

[49] J. Serrand, M.-P. Sunyach, S. Negrier, C. Carrie, and R. Tanguy, “Stereotactic body radiation therapy (SBRT) on spine metastases from renal cell carcinomas (RCC): clinical results and impact of upfront vs salvage SBRT,” Journal of Clinical Oncology, vol. 34, no. 15, p. e16073, 2016.

[50] S. Funayama, H. Onishi, K. Kuriyama et al., “Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiotherapy,” Technology in Cancer Research & Treatment, vol. 18, Article ID 1180781192, 2019.

[51] G. K. Hunter, E. H. Balagamwala, S. A. Koyfman et al., “The efficacy of external beam radiotherapy and stereotactic body radiotherapy (SBRT) for painful spinal metastases from renal cell carcinoma,” International Journal of Radiation Oncology* Biology* Physics, vol. 81, no. 2, pp. S649–S650, 2011.

[52] M. R. M. Sun, A. Brook, M. F. Powell et al., “Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors,” American Journal of Roentgenology, vol. 206, no. 3, pp. 544–553, 2016.

[53] B. Hirshman, B. Wilson, M. A. Ali et al., “Optimal radiation dose for treatment of melanoma and renal cell carcinoma metastases,” Neuro-Oncology, vol. 18, no. 6, p. 34, 2016.

[54] J. Bates, P. Youn, C. R. Peterson, K. Y. Usuki, and M. T. Milano, “Efficacy of stereotactic radiosurgery (SRS) in the treatment of brain metastases from melanoma and renal cell carcinoma (RCC),” International Journal of Radiation Oncology* Biology* Physics, vol. 90, no. 4, pp. S307, 2014.

[55] S. C. Formenti and S. Demaria, “Combining radiotherapy and cancer immunotherapy: a paradigm shift,” INCI: Journal of the National Cancer Institute, vol. 105, no. 4, pp. 256–265, 2013.

[56] A. B. Sharabi, M. Lim, T. L. DeWeese, and C. G. Drake, “Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy,” The Lancet Oncology, vol. 16, no. 13, pp. e498–e509, 2015.

[57] C. T.-S. Victor, A. J. Rech, A. Maity et al., “Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer,” Nature, vol. 520, no. 7547, pp. 373–377, 2015.

[58] S. S. Park, H. Dong, X. Liu et al., “PD-1 restrains radiotherapy-induced abscopal effect,” Cancer Immunology Research, vol. 3, no. 6, pp. 610–619, 2015.
[59] S. F. Ngiow, G. A. McArthur, and M. J. Smyth, "Radiotherapy complements immune checkpoint blockade," *Cancer Cell*, vol. 27, no. 4, pp. 437–438, 2015.

[60] R. Hannan, D. Ishihara, K. Louder et al., "Phase II trial of high-dose interleukin-2 (IL-2) and stereotactic radiation therapy (SABR) for metastatic clear cell renal cell carcinoma (ccRCC): interim analysis," *Journal of Clinical Oncology*, vol. 34, no. 2, p. 532, 2016.

[61] G. Xie, D. Gu, L. Zhang, S. Chen, and D. Wu, "A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma," *Cancer Biology & Therapy*, vol. 18, no. 8, pp. 547–551, 2017.

[62] Q. LaPlant, C. Deselm, N. A. Lockney, J. Hsieh, and Y. Yamada, "Potential abscopal response to dual checkpoint blockade in RCC after reirradiation using dose-painting SBRT," *Practical Radiation Oncology*, vol. 7, no. 6, pp. 396–399, 2017.

[63] J. M. Bauml, R. Mick, C. Ciunci et al., "Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial," *JAMA Oncology*, vol. 5, no. 9, p. 1283, 2019.

[64] S. Manohar, P. Kompotiatis, C. Thongprayoon, W. Cheungpasitporn, J. Herrmann, and S. M. Herrmann, "Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis," *Nephrology Dialysis Transplantation*, vol. 34, no. 1, pp. 108–117, 2019.

[65] A. C. Shirali, M. A. Perazella, and S. Gettinger, "Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients," *American Journal of Kidney Diseases*, vol. 68, no. 2, pp. 287–291, 2016.

[66] L. Bottlaender, A.-L. Breton, L. de Laforcade, F. Dijoud, L. Thomas, and S. Dalle, "Acute interstitial nephritis after sequential ipilimumab-nivolumab therapy of metastatic melanoma," *Journal for Immunotherapy of Cancer*, vol. 5, no. 1, p. 57, 2017.

[67] Y. Wang, S. Zhou, F. Yang et al., "Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials," *JAMA Oncology*, vol. 5, no. 7, p. 1008, 2019.

[68] L. W. Pfannenstiel, C. McNeilly, C. Xiang et al., "Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma," *OncolImmunology*, vol. 8, no. 1, Article ID e1507669, 2019.

[69] B. Murphy, J. Walker, S. Bassale et al., "Concurrent radiosurgery and immune checkpoint inhibition: improving regional intracranial control for patients with metastatic melanoma," *American Journal of Clinical Oncology*, vol. 42, no. 3, pp. 253–257, 2019.

[70] J. Lan, R. Li, L.-M. Yin et al., "Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy," *International Journal of Radiation Oncology*Biology*Physics*, vol. 101, no. 1, pp. 74–87, 2018.

[71] X. Sun, T. Zhang, M. Li, L. Yin, and J. Xue, "Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: a mini review," *QJM: An International Journal of Medicine*, pp. 1–6, 2019.

[72] E. D. Brooks and J. Y. Chang, "Time to abandon single-site irradiation for inducing abscopal effects," *Nature Reviews Clinical Oncology*, vol. 16, no. 2, pp. 123–135, 2019.

[73] T. J. Harris, E. L. Hipkiss, S. Borzillary et al., "Radiotherapy augments the immune response to prostate cancer in a time-dependent manner," *The Prostate*, vol. 68, no. 12, pp. 1319–1329, 2008.

[74] E. B. Golden and S. C. Formenti, "Radiation therapy and immunotherapy: growing pains," *International Journal of Radiation Oncology*Biology*Physics*, vol. 91, no. 2, pp. 252–254, 2015.

[75] X. Sun, L. Deng, and Y. Lu, "Challenges and opportunities of using stereotactic body radiotherapy with anti-angiogenesis agents in tumor therapy," *Chinese Journal of Cancer Research*, vol. 30, no. 1, pp. 147–156, 2018.